Common lymphatic endothelial and vascular endothelial...

Details Common lymphatic endothelial and vascular endothelial... Common lymphatic endothelial and vascular endothelial...

2011-03-22

2011-03-22

Haddad, Maher M (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S144100

Reexamination Certificate

active

07910097

ABSTRACT:
A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.

REFERENCES:
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5840844 (1998-11-01), Lasky et al.
patent: 6166179 (2000-12-01), Rice et al.
patent: 6713059 (2004-03-01), Kende et al.
patent: 7354577 (2008-04-01), Jalkanen et al.
patent: 2003/0108984 (2003-06-01), Naor et al.
patent: WO 00/39166 (2000-07-01), None
Irjala et al. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 2003; 63: 4671-6.
Karikoski et al., Clever-1 Controls the Cell Traffic via Afferent Lymphatic Vessels. Scandinavian Society for Immunology, 37thAnnual Meeting Turku, Finland, Jun. 6-9, 2007, pp. 604-605, Abstract No. 41.
Taupitz et al ., Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits. AJR Am J Roentgenol. Jul. 1993;161(1):193-200.
Sakata et al. Experimental hypersensitivity pneumonitis in rabbits induced by Trichosporon cutaneum: role of local cellular and humoral immune responses. J Clin Lab Immunol. Apr. 1988;25(4):191-9. (Abstract ).
Starz et al., Secondary lymph node involvement from primary cutaneous large B-cell lymphoma of the leg: sentinel lymph nodectomy as a new strategy for staging circumscribed cutaneous lymphomas. Cancer. Jan. 1, 1999;85(1):199-207.
Braunwald., Harrison's Principles of Internal Medicine., 1987, 11thEdition. pp. 272-273.
Irjala, H., et al., “Cell traffic in the lymphatic system can be inhibited by blocking the function of adhesion molecule CLEVER-1,” 4th Amsterdam ZOO-meeting: Cell Adhesion and Migration in Inflammation and Cancer, Oct. 4-7, 2006, Amsterdam, Netherlands.
Politz, O., et al., “Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues,”Biochem. J. 362:155-164, Portland Press (Feb. 2002).
Adachi, H. and Tsujimoto, M., “FEEL-1, a Novel Scavenger Receptor with in Vitro Bacteria-binding and Angiogenesis-modulating Activities,”J. Biol. Chem. 277:34264-34270, The American Society for Biochemistry and Molecular Biology, Inc. (Sep. 2002).
Carman, C.V. and Springer, T.A., “A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them,”J. Cell Biol. 167:377-388, Rockefeller University Press (Oct. 2004).
Engelhardt, B. and Wolburg, H., “Transendothelial migration of leukocytes: through the front door or around the side of the house?,”Eur. J. Immunol. 34:2955-2963, VCH Verlagsgesellschaft (Nov. 2004).
Gordon, K.B., et al., “Efalizumab for Patients With Moderate to Severe Plaque Psoriasis,”JAMA290:3073-3080, American Medical Association (Dec. 2003).
Irjala, H., et al., “The same endothelial receptor controls lymphocyte traffic both in vascular and lymphatic vessels,”Eur. J. Immunol. 33:815-824, VCH Verlagsgesellschaft (Mar. 2003).
Johnansson, I.H., et al, “Mechanisms of lymphocyte exit from lymphoid tissues,”Immunol. Lett., Abstracts of the 14th European Immunology Meeting EFIS2000:170, Elsevier/North Holland Biomedical Press (2000).
Lebwohl, M., et al., “A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis,”N. Engl. J. Med. 349:2004-2013, Massachusetts Medical Society (Nov. 2003).
Lerner, R.A., et al., “Tapping the immunological repertoire to produce antibodies of predetermined specificity,”Nature299:593-596, Nature Publishing Group (1982).
Nagase, T., et al., “Prediction of the Coding Sequences of Unidentified Human Genes. VI. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain,”DNA Res. 3:321-329, Kazusa DNA Research Institute and Universal Academy Press (1996).
Nieminen, M., et al., “Vimentin function in lymphocyte adhesion and transcellular migration,”Nat. Cell Biol. 8:156-162 and Supplementary Information pp. 1-3, Nature Publishing Group (Feb. 2006).
Norman, M.U. and Kubes, P., “Therapeutic intervention in inflammatory diseases: a time and place for anti-adhesion therapy,”Microcirculation12:91-98, Taylor & Francis (Jan.-Feb. 2005).
Polman, C.H., et al., “A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis,”N. Engl. J. Med. 354:899-923, Massachusetts Medical Society (Mar. 2006).
Rudick, R.A., et al., “Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis,”N. Engl. J. Med. 354:911-923, Massachusetts Medical Society (Mar. 2006).
Salmi, M., et al., “CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium,”Blood104:3849-3857, American Society of Hematology (Dec. 2004).
Sandborn, W.J., et al., “Natalizumab Induction and Maintenance Therapy for Crohn's Disease,”N. Engl. J. Med. 353:1912-1925, Massachusetts Medical Society (Nov. 2005).
International Search Report for International Application No. PCT/FI03/00010, mailed Apr. 16, 2003, Swedish Patent Office, Stockholm Sweden.
International Preliminary Report on Patentability for International Application No. PCT/FI03/000010, completed Feb. 10, 2004, Swedish Patent Office, Stockholm, Sweden.
Database GSN Online, Accession No. AAA57362, retrieved from EBI (2000).
Database GSP Online, Accession No. AAY93910, retrieved from EBI (2000).
Database EM-HUM Online, Accession No. HSD433, retrieved from EBI (created 1996, as updated Jul. 5, 2002).
Database EM-HUM Online, Accession No. HSA275213, retrieved from EBI (created 1999, as updated Feb. 14, 2003).
Database SWALL Online, Accession No. Q9NY15, retrieved from EBI (created 2000, as updated Jun. 1, 2003).
Database SWALL Online, Accession No. Q93072, retrieved from EBI (created 1997, as updated Jun. 1, 2003).
Database SWALL Online, Accession No. Q93073, retrieved from EBI (created 1997, as updated Jul. 5, 2004).
Sequence comparison between Database GSN Online, Accession No. AAA57362, retrieved from EBI (Document NPL18) (2000) with SEQ. ID. No. 1 lacking nucleotides 2914-3009.
Sequence comparison between Database GSN Online, Accession No. AAA57362, retrieved from EBI (Document NPL18) (2000) with SEQ. ID. No. 1.
Sequence comparison between Database GSP Online, Accession No. AAY93910, retrieved from EBI (Document NPL19) (2000) with SEQ. ID. No. 1 lacking nucleotides 2914-3009.
Sequence comparison between Database GSP Online, Accession No. AAY93910, retrieved from EBI (Document NPL19) (2000) with SEQ. ID. No. 1.
Sequence comparison between Database EM-HUM Online, Accession No. HSD433, retrieved from EBI (Document NPL20) (created 1996, as updated Jul. 5, 2002) with SEQ ID No. 1.
Sequence comparison between Database EM-HUM Online, Accession No. HSA275213, retrieved from EBI (Document NPL21) (created 1999, as updated Feb. 14, 2003) with SEQ. ID. No. 1.
Sequence comparison between Database SWALL Online, Accession No. Q9NY15, retrieved from EBI (Document NPL22) (created 2000, as updated Jun. 1, 2003) with the protein sequence of SEQ. ID. No. 1.
Sequence comparison between Database SWALL Online, Accession No. Q93072, retrieved from EBI (Document NPL23) (created 1997, as updated Jun. 1, 2003) with the protein sequence of SEQ ID No. 1.
Kzhyshkowska, J., et al., “Stabilin-1, a homeostatic scavenger receptor with multiple functions,”J. Cell. Mol. Med. 10:635-649, “Carol Davila” University Press (Jul.-Sep. 2006).
Prevo, R., et al., “Rapid Plasma Membrane-Endosomal Trafficking of the Lymph Node Sinus and High Endothelial Venule Scavenger R

Affiliated with

Also associated with

Rating

Common lymphatic endothelial and vascular endothelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Common lymphatic endothelial and vascular endothelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Common lymphatic endothelial and vascular endothelial... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2683219